Thursday, October 01, 2015

          Drug Wars: A New Generation of Generic Pharmaceutical Delay

          New paper by Professor Robin Feldman and Research Fellow Evan Frondorf follows evolution of strategies used by pharmaceutical companies to delay entrance of generic drugs, revealing clever “games” being played out in courts, conference rooms, and laboratories across the world.
          Sample alt tag.
          “Even a few months of generic delay for one drug can prevent consumers from realizing hundreds of millions of dollars in savings,” says Feldman.

          Recent news detailing enormous spikes in prices for some drugs has brought the issue of prescription drug access back into focus with leading presidential candidates calling for reform in the midst of public outrage.

          High prices are not just plaguing a few medications with limited applications — nationwide spending on drugs increased 12 percent in just the last year. One reason for climbing prices might be a lack of generic competition for some drugs.

          When the US introduced a regulatory pathway in the 1980s to speed generic drugs to market, it ushered in a new era for medicine. Now, more than 80% of drugs have a generic equivalent, and consumers save hundreds of billions of dollars each year through generic prescriptions. However, as drugs face patent expiration or the threat of generic competition, pharmaceutical companies have long taken drastic measures to keep generic versions of their drugs off the market.

          A new paper by UC Hastings Professor Robin Feldman and Research Fellow Evan Frondorf follows the evolution of strategies used by pharmaceutical companies to delay the entrance of generic drugs, revealing clever “games” being played out in courts, conference rooms, and laboratories across the world.

          The paper — titled “Drug Wars: A New Generation of Generic Pharmaceutical Delay” — is forthcoming in the Harvard Journal on Legislation. A draft is available at http://ssrn.com/abstract=2659308

          “Even a few months of generic delay for one drug can prevent consumers from realizing hundreds of millions of dollars in savings,” says Feldman. “In turn, that additional period of exclusivity — an extended monopoly period — is extremely valuable to a pharmaceutical company.”

          Early strategies focused on making deals with prospective generic manufacturers to stay out of the market, commonly known as “reverse payments” and “pay-for-delay settlements.” But as these settlements have come under intense government and public scrutiny, Feldman and Frondorf show how companies have moved away from these “Generation 1.0” settlements, employing ever-more complex strategies.

          “Generation 2.0” strategies employ the pay-for-delay model while obscuring the monetary payment behind side deals and other considerations, and include what the authors call “boy scout clauses” — agreements to behave honorably that actually mask anticompetitive collusion. And the newest generation moves from collusion to obstruction. “Generation 3.0” makes use of complicated administrative processes, regulatory schemes, and minimal drug modifications to prevent generics from getting to market. They include the following:

          • “Product hopping” — a last-minute switch to a “new and improved” form of a drug just before generic competition is scheduled to begin on the original drug
          • “REMS delay” — using FDA safety protocols as an excuse not to cooperate with generic drug makers
          • “Citizen petition” — filing petitions with the FDA claiming that a generic drug should not be approved, merely to delay its entry while the FDA reviews the petition

          The paper ends with a call for reform, exploring ideas for how a new generic entry pathway might be structured.

          “To incentivize continued drug development, pharmaceutical companies must have a chance to recoup their research costs,” says Frondorf. “But the patent system is built on inventions eventually reaching the public domain, and actions meant to block generic entry are contrary to the interests of Congress, the patent system, and, importantly, consumers who would otherwise benefit from lower-cost generics.”

          ###

          Go to News Archive

          Share this Story

          Share via Facebook
          Share via TwitterShare via EmailPrint Friendly Version

          Other Recent Stories/ RSS

          Tuesday, March 21, 2017

          UC Hastings LL.M. student Simren Delaney works with early stage Bay Area startups

          Now in its 7th year, the Startup Legal Garage enables UC Hastings students to work with early stage Tech and BioTech companies to provide them with corporate and intellectual property legal services under the supervision of leading attorneys throughout the Bay Area.
          Tuesday, March 14, 2017

          Message from Dean Faigman: US News Rankings

          While it is an annual rite of spring for deans to celebrate or lament the widely variable swings in rankings from year-to-year, UC Hastings must keep its eyes on what counts. We are doing that.
          Tuesday, March 07, 2017

          What Worked for Us May Work for You: Alumni Share Bar Success Stories for New Blog

          UC Hastings launches the Bar Passage Success Stories and Strategies blog.
          Monday, March 06, 2017

          UC Hastings Ranks #29 in National Law Journal's Top 50 Go-To Law Schools Report

          The annual "Go-To" report identifies the U.S. law schools with the most recent grads joining the nation’s largest law firms as associates.
          Friday, March 03, 2017

          Ben Bartlett: Be About It

          “Only crazy people change the world and it’s my duty to change the world.” A day in the life with Ben Bartlett ’14.
          Go to News Archive